PSB-12379 ditriethylamine salt, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).

CD73-IN-18 (compound 35j) is an orally effective inhibitor of the extracellular 5'-nucleotidase (CD73) enzyme. It can be utilized in anticancer research.

CD73-IN-16 (compound 18) acts as an inhibitor of hCD73, exhibiting an IC50 value of 0.28 μM.

CD73-IN-3 (LY-3475070) is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.

CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor.

Dresbuxelimab (AK-119), an IgG-κ monoclonal antibody, selectively targets CD73 and is commonly produced using a Chinese Hamster Ovary (CHO) cell expression system [1].

AB-680, a highly potent, reversible, and selective inhibitor of CD73 (an ectonucleotidase, Ki: 4.9 pM for hCD73) with anti-tumor activity, displays >10,000-fold selectivity over related ectonucleotidases CD39.

Oleclumab (MEDI9447) is a human anti-CD73 monoclonal antibody with anticancer activity that inhibits the extracellular enzyme CD73 nucleic acid exonuclease activity, inhibits the adenosine pathway, and can be used for the study of metastatic desmoplasia-resistant prostate cancer.